Skip to main content
SpringerLink
Log in

Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer

  • Original Articles
  • Oestrogen Receptors and Chemotherapy
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The value of estrogen receptor (ER) status in the prediction of tumor response to combination chemotherapy was retrospectively analyzed in breast cancer patients selected for prospective controlled trials of chemotherapy (85 with advanced disease and 256 with operable tumors). All patients were previously untreated with either chemotherapy or endocrine therapy, and in all instances drug therapy was applied at the time of primary treatment. The ER status was considered positive in 54% of women with advanced disease and in 70% of women with operable breast tumor and positive axillary nodes, respectively. About 12% of patients were considered to have borderline ER. The response to drug therapy (complete plus partial remission in advanced breast cancer and 3-year relapse-free survival after mastectomy, respectively) was not significantly different between ER+ and ER—tumors. The comparative results of ER+ vs ER—patients were similar whether the cutoff point for ER+ tumors was >5 or >10 fmol/mg cytosol protein. The present results indicate that in advanced and early breast cancer combination chemotherapy is effective regardless of ER status. Therefore, in the presence of ER+ tumors there is no reason to delay the early administration of effective chemotherapy. This is particularly true both in the presence of rapidly progressing metastatic disease and in the adjuvant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allegra JC, Simon R, Lippman ME (1979) The association between steroid hormone receptor status and the disease-free interval in breast cancer. In: Salmon SE, Jones SE (eds.) Adjuvant therapy of cancer, Vol. II. Grune & Stratton, New York pp. 47–54

    Google Scholar 

  2. Bonadonna G, Valagussa P, Rossi A, Zucali R, Tancini G, Bajetta E, Brambilla C, De Lena M, Di Fronzo G, Banfi A, Rilke F, Veronesi U (1978) Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol 5:450

    Google Scholar 

  3. Brambilla C, Valagussa P, Bonadonna G (1978) Sequential combination chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 1:35

    Google Scholar 

  4. Carter SK (1979) The dilemma of estrogen receptors and the response rate to cytotoxic chemotherapy. A problem of comparability analysis. Cancer Clin Trials 2:49

    Google Scholar 

  5. Cooke T, George D, Shields R, Maynard P, Griffiths K (1979) Oestrogen receptors and prognosis in early breast cancer. Lancet 1:995

    Google Scholar 

  6. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G (1978) Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1:53

    Google Scholar 

  7. De Lena M, Zucali R, Varini M, Rovini D, Viganotti G, Bonadonna G, Veronesi U (1979) Combined-modality approach in locally advanced breast cancer (T3b-T4). Proc Am Assoc Cancer Res 20:172 (Abstract 693)

    Google Scholar 

  8. Di Fronzo G, Bertuzzi A, Ronchi E (1978) An improved criterion for the evaluation of estrogen receptor binding data in human breast cancer. Tumori 64:259

    Google Scholar 

  9. EORTC Breast Cancer Cooperative Group (1973) Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 9:379

    Google Scholar 

  10. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. (A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland.) Eur J Cancer 13:89

    Google Scholar 

  11. Hilf R, Feldstein ML, Gibson SL, Savlov ED (1979) Does estrogen receptor status have prognostic value for recurrence or chemotherapy response in breast cancer? Proc Am Soc Clin Oncol 20:298 (Abstract C-26)

    Google Scholar 

  12. Jonat W, Maass H (1978) Some comments on the necessity of receptor determination in human breast cancer. Cancer Res 38:4305

    Google Scholar 

  13. Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ (1978) Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330

    Google Scholar 

  14. Knight WA, III, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669

    Google Scholar 

  15. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Hoan MTD, Aitken SC, Warren R (1978) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223

    Google Scholar 

  16. McGuire WL (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5:428

    Google Scholar 

  17. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163

    CAS  PubMed  Google Scholar 

  18. Meyer JS, Rao BR, Steven SC, White WL (1977) Low incidence of estrogen receptors on breast carcinomas with rapid rates of cellular replication. Cancer 40:2290

    Google Scholar 

  19. Rich MA, Furmanski P, Brooks SC, Breast Cancer Prognostic Study Surgery and Pathology Associates (1978) Prognostic value of estrogen receptor determinations in patients with breast cancer. Cancer Res 38:4296

    Google Scholar 

  20. Rosner D, Nemoto T (1979) A randomized study of two and three drug regimens in relation with estrogen receptors in metastatic breast cancer. Proc Am Assoc Cancer Res 20:46 (Abstract 184)

    Google Scholar 

  21. Rossi A, Bonadonna G, Tancini G, Bajetta E, Marchini S, Valagussa P, Veronesi U (1979) Trials of adjuvant chemotherapy in breast cancer. The experience of the Istituto Nazionale Tumori of Milan. Eur J Cancer (In press)

  22. Rubens RD, King RJB (1979) Oestrogen receptors and response to cytotoxic chemotherapy. Proc Am Soc Clin Oncol 20:304 (Abstract C-52)

    Google Scholar 

  23. Tancini G, Bajetta E, Marchini S, Valagussa P, Bonadonna G, Veronesi U (1979) Operable breast cancer with positive axillary nodes (N+): results of 6 vs 12 cycles of adjuvant CMF in premenopausal women. Proc Am Assoc Cancer Res 20:172 (Abstract 695)

    Google Scholar 

  24. Walt AJ, Singhakowinta A, Brooks SC, Cortez A (1976) The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery 80:506

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Nazionale Tumori, Via Venezian, 1, 20133, Milano, Italy

    G. Bonadonna, Pinuccia Valagussa, G. Tancini & G. Di Fronzo

Authors
  1. G. Bonadonna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pinuccia Valagussa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Tancini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Di Fronzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonadonna, G., Valagussa, P., Tancini, G. et al. Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer. Cancer Chemother. Pharmacol. 4, 37–41 (1980). https://doi.org/10.1007/BF00255456

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00255456

Keywords

Search

Navigation